Figure 3

Alternation of colon permeability after administration of Uro A. FITC–Dextran was used to investigate the alternation of colon permeability. (a) The concentration of FITC-dextran (4 kDa) in the portal vein shows that the plasma FITC-dextran level in the Uro A group is significantly lower than that in the control group (n = 6, control group; 0.43 ± 0.07 µg/mL, Uro A group; 0.33 ± 0.03 µg/mL, p = 0.013, Wilcoxon rank sum test). (b) The mRNA expression of tight junction proteins in the colon epithelium shows that the levels of zo-1, zo-2, occludin, JAM, and claudin 1, 2, 3, 4, and 7 do not differ significantly between the Uro A and control groups (n = 6, zo1: control group; 1.00 ± 0.12, Uro A group; 1.11 ± 0.03, p = 0.68, zo2: control group; 1.00 ± 0.07, Uro A group; 0.97 ± 0.05, p = 0.53, occludin: control group; 1.00 ± 0.10, Uro A group; 1.10 ± 0.03, p = 0.68, JAM: control group; 1.00 ± 0.11, Uro A group; 1.17 ± 0.07, p = 0.30, claudin1: control group; 1.00 ± 0.19, Uro A group; 1.76 ± 0.44, p = 0.30, claudin2: control group; 1.00 ± 0.11, Uro A group; 1.19 ± 0.07, p = 0.40, claudin3: control group; 1.00 ± 0.13, Uro A group; 1.10 ± 0.05, p = 0.40, claudin4: control group; 1.00 ± 0.17, Uro A group; 0.93 ± 0.12, p = 1.00, claudin7: control group; 1.00 ± 0.07, Uro A group; 1.10 ± 0.06, p = 0.68, Wilcoxon rank sum test). Uro A, urolithin A; FITC, fluorescein isothiocyanate; mRNA, messenger RNA.